Affordable Access

Treatment of experimental subcutaneous human melanoma with a replication-restricted herpes simplex virus mutant.

Authors
Type
Published Article
Journal
Journal of Investigative Dermatology
Publisher
Elsevier
Volume
108
Issue
6
Pages
933–937
Source
Kesari Lab
License
Unknown

Abstract

Modified, non-neurovirulent herpes simplex viruses (HSV) have shown promise for the treatment of brain tumors, including intracranial melanoma. In this report, we show that HSV-1716, an HSV-1 mutant lacking both copies of the gene coding-infected cell protein 34.5 (ICP 34.5), can effectively treat experimental subcutaneous human melanoma in mice. In vitro, HSV-1716 replicated in all 26 human melanoma cell lines tested, efficiently lysing the cells. Therapeutic infection of subcutaneous human melanoma nodules with HSV-1716 led to viral replication that was restricted to tumor cells by immunohistochemistry. Moreover, HSV-1716 treatment significantly inhibited progression of preformed subcutaneous human melanoma nodules in SCID mice and caused complete regression of some tumors. This work expands the potential scope of HSV-1-based cancer therapy.

Report this publication

Statistics

Seen <100 times